An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project

Annals of Emergency Medicine

Volumn 60, Issue 4, 2012, Pages 451-457

  Meurer, William J ^a   Lewis, Roger J ^b,d   Tagle, Danilo ^c   Fetters, Michael D ^a   Legocki, Laurie ^a   Berry, Scott ^d   Connor, Jason ^d   Durkalski, Valerie ^e   Elm, Jordan ^e   Zhao, Wenle ^e   Frederiksen, Shirley ^a   Silbergleit, Robert ^a   Palesch, Yuko ^e   Berry, Donald A ^d,f   Barsan, William G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c National Institutes of Neurological Disorders and Stroke   (United States)

^d BERRY CONSULTANTS   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADAPTIVE DESIGN ACCELERATING PROMISING PROJECT; ARTICLE; BAYESIAN LEARNING; CLINICAL PRACTICE; FALSE NEGATIVE RESULT; HUMAN; MEDICAL DEVICE; NATIONAL HEALTH ORGANIZATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PILOT STUDY; PRIORITY JOURNAL; PROBABILITY; QUANTITATIVE DIAGNOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; SAMPLE SIZE; STUDY DESIGN; VISUAL ANALOG SCALE;

CLINICAL TRIALS, PHASE II AS TOPIC; DATA INTERPRETATION, STATISTICAL; EARLY TERMINATION OF CLINICAL TRIALS; HUMANS; INTERDISCIPLINARY COMMUNICATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84866735197     PISSN: 01960644     EISSN: 10976760     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2012.01.020     Document Type: Article

References (29)

1. J. Quinlan, B. Gaydos, J. Maca Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development Clin Trials 7 2010 167 173
2. Advancing Regulatory Science through Novel Research and Science-Based Technologies (U01) http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-10-006. html Accessed September 14, 2011.
3. L. Cearnal The birth of the NETT: NIH-funded network will launch emergency neurological trials Ann Emerg Med 48 2006 726 728
4. Food and Drug Administration Challenge and opportunity on the critical path to new medical products (March 2004) http://www.fda.gov/downloads/ ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/ucm113411.pdf Accessed September 14, 2011.
5. J.A. DiMasi, R.W. Hansen, H.G. Grabowski The price of innovation: new estimates of drug development costs J Health Econ 22 2003 151 185
6. D.W. Light, R.N. Warburton Extraordinary claims require extraordinary evidence J Health Econ 24 2005 1030 1033
7. Food and Drug Administration Critical path opportunities report (March 2006) http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/ CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM077254.pdf Accessed April 25, 2010.
8. S.J. Nass, H.L. Moses A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program 2010 National Academy Press Washington, DC
9. Food and Drug Administration Guidance for industry: adaptive design clinical trials for drugs and biologics http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf Accessed April 25, 2010.
10. V. Dragalin Adaptive designs: terminology and classification Drug Informat J 40 2006 425 435
11. P. Gallo, C. Chuang-Stein, V. Dragalin Adaptive designs in clinical drug development: an executive summary of the PhRMA Working Group J Biopharm Stat 16 2006 275 283
12. H. Hung, R.T. O'Neill, S.J. Wang A regulatory view on adaptive/flexible clinical trial design Biom J 48 2006 565 573
13. J. Arrowsmith Trial watch: phase III and submission failures: 2007-2010 Nat Rev Drug Discov 10 2011 87
14. Z. Antonijevic, J. Pinheiro, P. Fardipour Impact of dose selection strategies used in phase II on the probability of success in phase III Stat Biopharm Res 2 2010 469 486
15. A.D. Barker, C.C. Sigman, G.J. Kelloff I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy Clin Pharmacol Ther 86 2009 97 100
16. M. Krams, K.R. Lees, D.A. Berry The past is the future Stroke 36 2005 1341 1347
17. D.A. Berry, P. Mueller, A.P. Grieve Adaptive bayesian designs for dose-ranging drug trials Case Studies Bayesian Stat 5 2001 99 181
18. S.M. Berry, W. Spinelli, G.S. Littman A bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug Clin Trials 7 2010 121 135
19. B. Bornkamp, F. Bretz, A. Dmitrienko Innovative approaches for designing and analyzing adaptive dose-ranging trials J Biopharm Stat 17 2007 965 995
20. M. Bayarri, J.O. Berger The interplay of bayesian and frequentist analysis Stat Sci 19 2004 58 80
21. D.A. Berry Bayesian clinical trials Nat Rev Drug Discov 5 2006 27 36
22. D.A. Berry, D.K. Stangl Bayesian methods in health-related research Bayesian Biostat 1996 3 66
23. Chevret S. Bayesian adaptive clinical trials: a dream for statisticians only? Stat Med. In press.
24. S. Biswas, D.D. Liu, J.J. Lee Bayesian clinical trials at the University of Texas MD Anderson cancer center Clin Trials 6 2009 205
25. B. Lipscomb, G. Ma, D.A. Berry Bayesian predictions of final outcomes: regulatory approval of a spinal implant Clin Trials 2 2005 325 333
26. D.A. Berry Statistics: a Bayesian perspective 1996 Duxbury Press Pacific Grove, CA
27. Adaptive clinical trials in oncology Nat Rev Clin Oncol 2011 http://www.nature.com/nrclinonc/journal/vaop/ncurrent/full/nrclinonc.2011.165. html Accessed February 8, 2012.
28. J.W. Creswell Research Design: Qualitative, Quantitative, and Mixed Methods Approaches 2009 Sage Publication Thousand Oaks, CA
29. J.W. Creswell, M.D. Fetters, V.L. Plano Clark Mixed methods intervention trials Mixed Methods Res Nurs Health Sci 2009 159 180